JETREA
Peakocriplasmin
BLAINTRAVITREALINJECTABLEPriority Review
Approved
Oct 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JETREA (ocriplasmin) is a recombinant engineered protease administered via intravitreal injection for the treatment of vitreomacular traction, including macular holes. It works by cleaving extracellular matrix proteins that cause vitreous adhesion to the retina. The drug represents a first-in-class pharmacologic approach to a previously surgery-only indication.
Peak
JETREA remains at peak commercial maturity with moderate competitive pressure (30/100), indicating a stable but challenged market position requiring focused commercial execution.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
Started Dec 2015
48 enrolled
Diabetic RetinopathyPosterior Vitreous DetachmentDisease Progression
Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion
Started May 2015
62 enrolled
Vitreomacular TractionVitreomacular Adhesion
Assessment of Patients Treated With JETREA® for Vitreomacular Traction
Started Apr 2014
628 enrolled
Vitreomacular TractionVitreomacular Adhesion
Career Relevance
Working on JETREA offers opportunity in a specialized ophthalmic market with deep relationships in retinal surgery and ophthalmology. The product's peak lifecycle stage means roles focus on market maintenance, competitive differentiation, and payer management rather than launch activities.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.